CliffBio
small molecule

AURLUMYN

ILOPROST

Loss of exclusivityJuly 2044latest FDA-listed patent expiry
CompanyBTG INTERNATIONAL INC

Drug detail

Brand nameAURLUMYN
Active ingredientILOPROST
Strength100MCG/ML (100MCG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2024
Marketing statusRX

Listed patents

PatentExpiresType
12409183July 2044use U-4263
12409184August 2041product

Regulatory exclusivity

CodeExpires
ODE-465February 2031
NPFebruary 2027

More from BTG INTERNATIONAL INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.